

## **Impression Welcomes Former Professional AFL footballer Liam Picken to Advisory Board**

Impression Healthcare Limited ('Impression', 'IHL' or the 'Company'), developer of four unique medicinal cannabis products and owner of INCANNEX™ cannabis oils, is delighted to announce that former professional AFL footballer Mr Liam Picken has joined Impression to assist with the development of IHL-216A for the treatment of concussion and traumatic brain injury.

Liam is a celebrated premiership winning AFL footballer, playing 198 games for the Western Bulldogs. Over the course of his career, Liam suffered numerous concussions and ultimately announced his retirement in April 2019 as a result of ongoing concussion symptoms. Those symptoms included an enduring headache that lasted approximately 18 months, ongoing blurred vision and sensitivity to light and noise.

Liam now works to educate and raise awareness around brain injuries. On Thursday the 5<sup>th</sup> of March, Liam featured on multiple platforms of Australian media, including the Herald Sun and Channel 9 News, for his decision to posthumously donate his brain for the purpose of concussion research.

As part of the Advisory Board, Liam has agreed to assist IHL with the following activities:

- The development of 'real world' aspects of the clinical program for IHL-216A,
- to liaise with the media about Impression's clinical program,
- to attend Impression meetings with partners, investors and program participants, and
- to work with Impression to develop a player wellbeing program.

**Mr Joel Latham, CEO and Managing Director of Impression said;** *"IHL-216A is our proprietary neuro-protective agent to be administered after a concussive event. It is designed to ameliorate the symptoms of, and damage caused by concussions, having a strong application in the physical sport setting. We're delighted that Liam has joined our team because his involvement will help to raise the profile of our endeavours to commercialise IHL-216A".*

**ENDS**

### **About Impression Healthcare Limited (ASX: IHL)**

Impression Healthcare Limited (IHL.ASX) is a first-in-class innovator and developer of a diversified mix of medicinal cannabis pharmaceutical products for global export potential. The Company is currently undertaking clinical programs to develop 4 uniquely formulated medicinal cannabis products for the treatment of Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury/Concussion, Temporomandibular Joint Disorder and Periodontitis (Gum Disease).

Each indication represents major global markets with significant yearly sales. 3 of the 4 indications currently have no existing registered pharmacotherapy (drug) treatment, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.

There is an established body of research validating the hypothesis for the cannabinoids being used in Impression's chosen therapeutic areas and IHL has a strong patent filing strategy as it develops its products in conjunction with its medical advisory board of global key opinion leaders.

Further to its clinical programs, Impression also has its Australian licenses in place to import, export and distribute medicinal cannabis products and has launched a line of EU GMP approved CBD oil products under the brand, "INCANNEX". The INCANNEX cannabis-based oils are sold under Impression's product supply and distribution agreement with Cannvalate Pty Ltd, which is the largest network of cannabis medicine prescribers in Australia.

Yielding growing revenues to Impression is its customised oral devices manufacturing business. The oral devices division delivers high-quality products both direct to the consumer and via a growing B2B preferred practitioner network of dentists.

**Investors:** [investors@impression.healthcare](mailto:investors@impression.healthcare)

**Website:** [www.impression.healthcare](http://www.impression.healthcare)